Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
April 26 2022 - 9:15AM
Petros Pharmaceuticals, Inc. (Petros, Nasdaq: PTPI), a leading
provider of therapeutics for men’s health, today announces it has
entered into a Sponsored Research Agreement (SRA) and an Option
Agreement with the Wellman Center of Massachusetts General Hospital
(“Mass General”), an affiliate of Harvard Medical School. Under the
agreement, researchers will evaluate incorporating the use of a
tissue-specific oxygenation sensor with the goal of monitoring and
understanding the success of Erectile Device Therapy. Accompanying
the Sponsored Research Agreement, Petros will enter into an
Agreement for an option to negotiate an exclusive license of the
tissue-specific oxygenation sensor within specific human tissues.
The Company plans to apply the technology to potentially enhance
its existing erectile device therapy.
“We believe what Mass General has developed is a truly landmark
achievement in immediate and highly-targeted bio-sensor feedback
technology,” said Fady Boctor, Petros Pharmaceuticals’ President
and Chief Commercial Officer. “This relationship with the Wellman
Center at Mass General has the potential to empower the male
patient with innovative technology to enhance at-home therapy in
the area of erectile dysfunction by demonstrating the effectiveness
of external devices in an additional non-invasive context.”
Both mobile and consumer-friendly, the sensor technology is
intended to offer the men’s health space the opportunity to enhance
at-home penile therapy with bio-sensor feedback, which can inform
both the patient and the practitioner of results in real time.
About Petros PharmaceuticalsPetros
Pharmaceuticals is committed to the goal of becoming a
world-leading specialized men's health company by identifying,
developing, acquiring, and commercializing innovative therapeutics
for men's health issues including, but not limited to erectile
dysfunction, endothelial dysfunction, psychosexual and psychosocial
ailments, Peyronie's disease, hormone health and substance use
disorders.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements are based
upon Petros Pharmaceuticals, Inc.’s (“Petros,” “we,” “our,” “us” or
the “Company”) management’s assumptions, expectations, projections,
intentions and beliefs about future events. In some cases,
predictive, future-tense or forward-looking words such as “intend,”
“develop,” “goal,” “plan,” “may,” “will,” “project,” “estimate,”
“anticipate,” “believe,” “expect,” “continue,” “potential,”
“opportunity,” “forecast,” “should” and similar expressions,
whether in the negative or affirmative, are intended to identify
forward-looking statements, but are not the exclusive means of
identifying such statements. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of risks
and uncertainties, including, without limitation, Petros’ ability
to execute on its business strategy, including its plans to develop
and commercialize its product candidates; Petros’ ability to comply
with obligations as a public reporting company; the ability of
Petros to timely and effectively implement controls and procedures
required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk
that the financial performance of Petros may not be as anticipated
by the merger transactions that resulted in the Company’s creation;
risks resulting from Petros’ status as an emerging growth company,
including that reduced disclosure requirements may make shares of
Petros common stock less attractive to investors; risks related to
Petros’ ability to continue as a going concern; risks related to
Petros’ dependence on the commercialization of a single product,
Stendra®, and on a single distributor thereof; risks related to
Petros’ commercial supply agreement with Vivus; and risks related
to Petros’ ability to obtain regulatory approvals for, or market
acceptance of, any of its products or product candidates.
Additional factors that could cause actual results to differ
materially from the results anticipated in these forward-looking
statements are contained in the Company’s periodic reports and in
other filings that the Company has filed, or may file, with the
U.S. Securities and Exchange Commission (the “SEC”) under the
headings “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and elsewhere.
The Company cautions readers that the forward-looking statements
included in this press release represent our beliefs, expectations,
estimates and assumptions only as of the date of hereof and are not
intended to give any assurance as to future results. New factors
emerge from time to time, and it is not possible for us to predict
all of these factors. Further, the Company cannot assess the effect
of each such factor on our business or the extent to which any
factor, or combination of factors, may cause actual results to be
materially different from those contained in any forward-looking
statement. Accordingly, you should not unduly rely on any
forward-looking statements.The Company undertakes no obligation to
update or revise any forward-looking statements contained in this
press release, whether as a result of new information, future
events, a change in our views or expectations or otherwise, except
as required by federal securities laws.
CONTACTS:Investors:CORE IRir@petrospharma.com
Media:Jules AbrahamCORE IR917-885-7378pr@coreir.com
Petros Pharmaceuticals (NASDAQ:PTPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Petros Pharmaceuticals (NASDAQ:PTPI)
Historical Stock Chart
From Apr 2023 to Apr 2024